Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Wessel ten Hagen"'
Autor:
Ida H. Hiemstra, Kim Santegoets, Maarten Janmaat, Wessel Ten Hagen, Rosanna Sanchez, Lauren Brady, Sieto Bosgra, Marije Overdijk, Jenny Chen, Katrine Fladeland Iversen, Torben Plesner, Esther Breij
Publikováno v:
HemaSphere, Vol 7, p e008261b (2023)
Externí odkaz:
https://doaj.org/article/4f633667bf9e4dc6b0f47f3a8fb66a88
Autor:
Ida H. Hiemstra, Kim C.M. Santegoets, Maarten L. Janmaat, Bart E.C.G. De Goeij, Wessel Ten Hagen, Sanne van Dooremalen, Peter Boross, Jeroen van den Brakel, Sieto Bosgra, Grietje Andringa, Berris van Kessel-Welmers, Dennis Verzijl, Richard G. Hibbert, Kristine A. Frerichs, Tuna Mutis, Niels W.C.J. van de Donk, Tahamtan Ahmadi, David Satijn, A. Kate Sasser, Esther C.W. Breij
Publikováno v:
EBioMedicine, Vol 93, Iss , Pp 104663- (2023)
Summary: Background: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surf
Externí odkaz:
https://doaj.org/article/f33bd39a5fdd41bc885381f56bdbe832
Autor:
Brian Elliot, Edith Szafer-Glusman, Wessel ten Hagen, Bart de Jong, Danita H. Schuurhuis, Christopher Chiu, Rajaa Snijdewint-Nkairi, A. Kate Sasser, Tahamatan Ahmadi, Julie Blaedel, Maria Jure-Kunkel, Roberto S. Oliveri, Esther C.W. Breij, Ida H. Hiemstra
Publikováno v:
Cancer Research. 81:1574-1574
B-cell non-Hodgkin lymphoma (B-NHL) is a heterogeneous disease with an unmet medical need for new efficacious, well tolerated, off-the-shelf therapies that can combine with standard of care (SOC) regimens. Epcoritamab (GEN3013; DuoBody®-CD3×CD20) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::858e0d94f09b6063e784e8464115aba6
https://doi.org/10.1158/1538-7445.am2021-1574
https://doi.org/10.1158/1538-7445.am2021-1574
Autor:
Jeroen van den Brakel, Ida H. Hiemstra, David Satijn, Sanne van Dooremalen, Maarten L. Janmaat, Esther C.W. Breij, Peter Boross, Tahamtan Ahmadi, Bart De Goeij, Laurens P. Kil, Sieto Bosgra, Grietje Andringa, Wessel ten Hagen, A. Kate Sasser
Publikováno v:
Blood. 136:19-20
HexaBody®-CD38 (GEN3014) is a next-generation CD38-specific IgG1 molecule with a hexamerization-enhancing mutation that leads to highly efficient induction of complement-dependent cytotoxicity (CDC) upon binding to CD38 positive tumor cells. HexaBod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a52b2b9f5088c09d60608426f2374f79
https://doi.org/10.1182/blood-2020-140313
https://doi.org/10.1182/blood-2020-140313